Asset Management One Co. Ltd. Raises Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Asset Management One Co. Ltd. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,844 shares of the company’s stock after purchasing an additional 3,057 shares during the period. Asset Management One Co. Ltd. owned 0.06% of IDEXX Laboratories worth $21,927,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. International Assets Investment Management LLC grew its stake in IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the period. Assenagon Asset Management S.A. grew its position in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares during the period. Seilern Investment Management Ltd purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $113,104,000. Worldquant Millennium Advisors LLC lifted its position in IDEXX Laboratories by 230.1% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after acquiring an additional 76,809 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in IDEXX Laboratories by 150.6% during the third quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company’s stock worth $54,693,000 after acquiring an additional 65,050 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IDXX shares. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 in the last ninety days. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Down 3.3 %

Shares of IDEXX Laboratories stock opened at $444.53 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a market cap of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company’s 50 day moving average is $430.95 and its 200 day moving average is $453.11.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.